
Can GLP-1 Treatment Be Personalized? What New Penn and Mayo Studies Actually Show
A Penn-led analysis compared seven cardiometabolic outcomes across GLP-1 trial programs, while Mayo researchers identified a possible obesity phenotype associated with a different retrospective tirzepatide response. Together they sharpen the research questions, but they do not create a consumer test or treatment selector.